Lung Cancer

Lung Cancer

GlaxoSmithKline has stopped a phase III trial of a novel lung cancer immunotherapeutic agent, after determining that it may not be possible to identify which genetic subgroups may benefit from the treatment.

A biomarker and five clinical factors help to predict which patients with nonsmall-cell lung cancer are at high risk for lung inflammation after radiotherapy.

The new ALK inhibitor certinib showed strong antitumor activity in a phase I expansion study of patients with advanced non-small-cell lung cancer (NSCLC).

In a phase I trial, non–small-cell lung cancer (NSCLC) patients with tumors that expressed PD-L1 had significantly better outcomes with MK-3475 therapy compared with patients with PD-L1–negative tumors.

In this interview we discuss the oncogenes driving the development of squamous cell carcinoma of the lung, a type of non-small-cell lung cancer.

Combining both cetuximab and bevacizumab with platinum-based chemotherapy showed strong efficacy in a phase II trial of patients with advanced non-small-cell lung cancer.

A combination regimen of erlotinib and the selective MET inhibitor tivantinib did not improve overall survival compared with erlotinib and placebo among patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer.


Subscribe to

CME Center

Earn CME Credits for reading Psychiatric Times articles. Click here to go to our free online CME activities.

Please Wait 20 seconds or click here to close